- SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
- SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
- SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
- SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
- SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
- SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
More ▼
Key statistics
On Friday, SpringWorks Therapeutics Inc (SWTX:NSQ) closed at 36.77, -31.81% below its 52-week high of 53.92, set on Mar 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 37.28 |
---|---|
High | 37.55 |
Low | 36.66 |
Bid | 30.00 |
Offer | 39.15 |
Previous close | 37.28 |
Average volume | 884.18k |
---|---|
Shares outstanding | 74.09m |
Free float | 70.19m |
P/E (TTM) | -- |
Market cap | 2.76bn USD |
EPS (TTM) | -5.15 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼